Long-acting β2 agonists as potential option in the treatment of acute exacerbations of COPD

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 4, 2003, Pages 197-201

  Cazzola, Mario ^a,c   Matera, Maria Gabriella ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NONE   (Italy)

Author keywords

Acute exacerbations; COPD; Formoterol; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; ISOPRENALINE; MESSENGER RNA; SALBUTAMOL; TERBUTALINE;

AIRFLOW; AIRWAY OBSTRUCTION; BETA ADRENERGIC STIMULATION; BRONCHODILATATION; BRONCHOSPASM; CARDIOVASCULAR SYMPTOM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAPHY MONITORING; GUINEA PIG; HEADACHE; HEART PALPITATION; HUMAN; LUNG FUNCTION; LUNG PARENCHYMA; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RESPIRATORY DISTRESS; REVIEW; SPUTUM; SYMPTOM; TRACHEA; TREATMENT FAILURE; TREMOR;

EID: 0037678807     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(03)00025-7     Document Type: Article

References (48)

1. Dewan N.A., Rafique S., Kanwar B., et al. Acute exacerbation of COPD: factors associated with poor outcome. Chest. 117:2000;662-671.
2. Pauwels R.A., Buist A.S., Calverley P.M.A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 163:2001;1256-1276.
3. Ikeda A., Nishimura K., Izumi T. Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease. Drugs Aging. 12:1998;129-137.
4. McCrory D.C., Brown C., Gelfand S.E., et al. Management of acute exacerbations of COPD. Chest. 119:2001;1190-1209.
5. Kuhl D.A., Agiri O.A., Mauro L.S. β-agonists in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Pharmacother. 28:1994;1379-1388.
6. Fromm R.E. Jr., Varon J. Acute exacerbations of obstructive lung disease. What to do when immediate care is crucial. Postgrad Med. 95:1994;101-106.
7. Emerman C.L., Cydulka R.K. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 29:1997;474-478.
8. Karpel J.P., Pesin J., Greenberg D., et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest. 98:1990;835-839.
9. Lloberes P., Ramis L., Montserrat J.M., et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 1:1988;536-539.
10. Bernasconi M., Brandolese R., Poggi R., et al. Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intensive Care Med. 16:1990;108-114.
11. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 152:1995;S77-S121.
12. Cazzola M., Matera M.G., Santangelo G., et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 89:1995;357-362.
13. Ullman A., Bergendal A., Linden A., et al. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium. Allergy. 47:1992;384-387.
14. Jeppsson A.B., Nilsson E., Waldeck B. Formoterol and salmeterol are both long acting compared to terbutaline in the isolated perfused and ventilated guinea-pig lung. Eur J Pharmacol. 257:1994;137-143.
15. Faulds D., Hollingshead L.M., Goa K.L. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 42:1991;115-137.
16. Ringdal N., Derom E., Wahlin-Boll E., et al. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med. 92:1998;1017-1021.
17. Cazzola M., Centanni S., Regolda S., et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther. 14:2001;41-45.
18. Pauwels R.A., Löfdahl C.-G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 337:1997;1405-1411.
19. 2-adrenoceptor expression in human lung. Eur J Pharmacol. 318:1996;123-129.
20. 2-agonists. Is there cause for concern? Drug Saf. 16:1997;295-308.
21. Naline E., Zhang Y., Qian Y., et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J. 7:1994;914-920.
22. Lemoine H., Overlack C., Kohl A., et al. Formoterol, fenoterol, and albuterol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding. Lung. 170:1992;163-180.
23. 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax. 51:1996;54-58.
24. 2-adrenoceptor expression in human lung. Eur J Pharmacol. 318:1996;123-129.
25. Cazzola M., Di Perna F., Noschese P., et al. Effects of a pre-treatment with conventional doses of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD. Eur Respir J. 10:1998;1337-1341.
26. 2 responses to fenoterol. Thorax. 51:1996;585-589.
27. Cazzola M., Di Perna F., D'Amato M., et al. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med. 95:2001;917-921.
28. Cazzola M., D'Amato M., Califano C., et al. Formoterol as dry powder oral inhalation in comparison with salbutamol metered dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther. 24:2002;595-604.
29. Cazzola M., Santus P., Matera M.G., et al. A single high dose of fomoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med. 2003;. in press.
30. Heimer D., Shim C., Williams M. The effect of sequential inhalations of metaproterenol aerosol in asthma. J Allergy Clin Immunol. 66:1980;75-77.
31. Britton J., Tattersfield A. Comparison of cumulative and non-cumulative techniques to measure dose-response curves for beta agonists in patients with asthma. Thorax. 39:1984;597-599.
32. Cazzola M., Matera M.G., D'Amato M., et al. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Pulm Pharmacol Ther. 2003;. in press.
33. Cazzola M., Santangelo G., Piccolo A., et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 7:1994;103-107.
34. Johnson M. The β-adrenoreceptor. Am J Respir Crit Care Med. 158:1998;S146-S153.
35. Cazzola M., Califano C., Di Perna F., et al. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Respir Med. 96:2002;790-795.
36. 2 agonists in the treatment of acute exacerbations of COPD. Clin Drug Invest. 22:2002;369-376.
37. Cazzola M., Matera M.G., Santangelo G., et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 89:1995;357-362.
38. 2-agonist bronchodilators. Med Toxicol. 1:1986;286-299.
39. Nelson H.S., Berkowitz R.B., Tinkelman D.A., et al. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med. 159:1999;1556-1561.
40. ® in patients with COPD. Respir Med. 96:2002;439-443.
41. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 4th ed. 1992;WB Saunders, Philadelphia, PA.
42. Maisel A.S., Michel M.C. β-Adrenergic receptors in congestive heart failure: present knowledge and future directions. Cardiology. 76:1989;338-346.
43. Johnson M., Butchers P.R., Coleman R.A., et al. The pharmacology of salmeterol. Life Sci. 52:1993;2131-2143.
44. Cazzola M., Imperatore F., Salzillo A., et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 114:1998;411-415.
45. Khoukaz G., Gross N.J. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease comparison with albuterol and ipratropium. Am J Respir Crit Care Med. 160:1999;1028-1030.
46. Ingram R.H. Jr., Krumpe P.E., Duffel G.M., et al. Ventilation-perfusion changes after aerosolized isoproterenol in asthma. Am Rev Respir Dis. 101:1970;364-370.
47. Wagner P.D., Dantzker D.R., Iacovoni V.E., et al. Ventilation-perfusion inequality in asymptomatic asthma. Am Rev Respir Dis. 118:1978;511-524.
48. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 117:2000;398S-401S.